

ELIQUIS for the Treatment of DVT/PE

**AMPLIFY: Phase III, Double-blind,
Randomized Clinical Trial**

**A Real-World, Observational, Retrospective
Database Analysis**

Independently funded by the University of Pennsylvania

DVT=deep vein thrombosis; PE=pulmonary embolism.

INDICATION¹

ELIQUIS is indicated for the treatment of adults with DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.

SELECTED IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

SELECT CHARACTERISTICS OF RANDOMIZED CLINICAL TRIALS AND REAL-WORLD DATA

RANDOMIZED CLINICAL TRIALS



REAL-WORLD OBSERVATIONAL STUDIES

- **Prospective design** with **prespecified**, well-defined inclusion/exclusion criteria, outcomes, and endpoints^{4,5}
- Patients are **randomly** assigned to treatment or comparator^{4,5}
- Randomized clinical trials are designed to show **causality** (ie, efficacy and safety data)⁶

- **Observational in nature** and use data from routine clinical practice^{5,7}
- Patients are **not randomized**^{5,7}
- Can only evaluate **association** and therefore unable to determine causality⁷

AMPLIFY: A PHASE III, DOUBLE-BLIND, RANDOMIZED CLINICAL NONINFERIORITY TRIAL²

Study objective¹:

To determine whether ELIQUIS was noninferior to enoxaparin/warfarin for the incidence of recurrent VTE* or VTE-related death.

5400 randomized patients with DVT and/or PE^{1,8}

ELIQUIS

10 mg orally twice daily for 7 days followed by 5 mg orally twice daily for 6 months

n=2693

enoxaparin/warfarin

Standard of care at the time; enoxaparin 1 mg/kg subcutaneously twice daily for at least 5 days (until INR \geq 2) followed by warfarin (target INR range, 2.0–3.0) orally for 6 months

n=2707

Primary efficacy endpoint: Recurrent VTE* or VTE-related death⁸

Primary safety endpoint: Major bleeding⁸

Select inclusion criteria: Objectively confirmed, symptomatic proximal DVT and/or PE.⁸

Select exclusion criteria^{1,8}:

- Patients who required:
 - Thrombectomy
 - Insertion of a caval filter
 - Use of a fibrinolytic agent
- Patients who had cancer and \geq 6 months of low-molecular-weight heparin treatment planned
- Patients with:
 - A life expectancy of <6 months
 - Creatinine clearance <25 mL/min
 - Significant liver disease
 - Mechanical valve
 - Atrial fibrillation
 - Active bleeding

Baseline characteristics: Approximately 90% of patients had an unprovoked DVT or PE at baseline, and the 10% of patients with a provoked DVT/PE were required to have an additional ongoing risk factor, which included a previous episode of DVT/PE, immobilization, history of cancer, active cancer, and known prothrombotic genotype. Patients were allowed to enter the study with or without prior parenteral anticoagulation (up to 48 hours).^{1,8}

Major bleeding was defined as clinically overt bleeding accompanied by at least one of the following^{2,8}:

- Fatal bleeding
- Critical site bleeding—Bleeding that occurred in at least one of the following critical sites: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal
- Transfusion—A transfusion of 2 or more units of packed red blood cells
- Hemoglobin decrease—A decrease in hemoglobin of 2 g/dL or more

*Recurrent symptomatic VTE (nonfatal DVT or nonfatal PE).⁸

DVT=deep vein thrombosis; INR=international normalized ratio; PE=pulmonary embolism; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

- **Increased Risk of Thrombotic Events after Premature Discontinuation:** Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

AMPLIFY: SELECT PATIENT BASELINE CHARACTERISTICS^{2,8}

	ELIQUIS (n=2691)	ENOXAPARIN/WARFARIN (n=2704)
MEAN AGE, YEARS (SD)	57.2 (16.0)	56.7 (16.0)
MALE SEX, % (N)	58.3% (1569)	59.1% (1598)
QUALIFYING DIAGNOSIS, % (N)		
DVT	65.0% (1749)	65.9% (1783)
PE	34.6% (930)	33.5% (906)
PE only	25.2% (678)	25.2% (681)
PE with DVT	9.4% (252)	8.3% (225)
EXTENSIVE PE* AT BASELINE, % (N/TOTAL PE[†])	38.4% (357/930)	36.0% (326/906)
RENAL IMPAIRMENT, % (N)		
Moderate (CrCl >30 to ≤50 mL/min)	6.0% (161)	5.5% (148)
Severe [‡] (CrCl ≤30 mL/min)	0.5% (14)	0.6% (15)
PREVIOUS VTE, % (N)	17.2% (463)	15.1% (409)

*PE was defined as extensive if there were ≥2 lobes involving ≥50% of vasculature for each lobe.⁸

[†]Sum of qualifying diagnosis of PE only and PE with DVT.⁸

[‡]Patients with CrCl <25 mL/min were excluded.⁸

CrCl=creatinine clearance; DVT=deep vein thrombosis; PE=pulmonary embolism; SD=standard deviation; VTE=venous thromboembolism.


SELECTED IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- **Bleeding Risk:** ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
 - Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
 - Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
 - The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available for adults. Please visit www.andexxa.com for more information on availability of a reversal agent.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

IN AMPLIFY, ELIQUIS DEMONSTRATED BOTH COMPARABLE EFFICACY AND SUPERIORITY IN MAJOR BLEEDING EVENTS VS ENOXAPARIN/WARFARIN¹



ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.¹

The incidence of VTE-related death in AMPLIFY for ELIQUIS and enoxaparin/warfarin was 0.4% and 0.6% of patients, respectively.¹

- Discontinuation rate due to bleeding events: 0.7% in ELIQUIS-treated patients vs 1.7% with enoxaparin/warfarin
- In AMPLIFY, the most commonly observed adverse reactions in ELIQUIS-treated patients (incidence $\geq 1\%$) were epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, and gingival bleeding

*Recurrent symptomatic VTE (nonfatal DVT or nonfatal PE).⁸

[†]Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.¹

[‡]RRR was calculated as $(1-RR) \times 100$. ARR is calculated as the difference between the incidences and is expressed as percentage points.

ARR=absolute risk reduction; CI=confidence interval; DVT=deep vein thrombosis; PE=pulmonary embolism; RR=relative risk; RRR=relative risk reduction; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION


WARNINGS AND PRECAUTIONS (cont'd)

- **Spinal/Epidural Anesthesia or Puncture:** Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

IN AMPLIFY, ELIQUIS DEMONSTRATED FEWER BLEEDING EVENTS ACROSS KEY SECONDARY ENDPOINTS, INCLUDING CRNM BLEEDING*¹



ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.¹

- In AMPLIFY, the discontinuation rate due to bleeding events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in the enoxaparin/warfarin-treated patients¹

CRNM bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with at least 1 of the following: medical intervention, contact with a physician, interruption of the study drug, or discomfort or impairment in carrying out activities of daily life.⁸

Minor bleeding was defined as all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM bleeding.²

*Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.¹

CRNM=clinically relevant nonmajor.

SELECTED IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- **Prosthetic Heart Valves:** The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
- **Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy:** Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

FOR THE TREATMENT OF DVT/PE

INDEPENDENTLY FUNDED,
RETROSPECTIVE COHORT,
REAL-WORLD DATABASE ANALYSIS³

Published in the *Annals of Internal Medicine*[®]

Risk for Recurrent Venous Thromboembolism and Bleeding With ELIQUIS Compared With XARELTO[®] (rivaroxaban): An Analysis of Real-World Data³

Independently funded by the University of Pennsylvania.³

TOTAL STUDY POPULATION: 37,236 VTE PATIENTS³

Annals of Internal Medicine[®] is a registered trademark of the American College of Physicians, Inc.

Xarelto[®] (rivaroxaban) is a registered trademark of Bayer Aktiengesellschaft.

Select text republished by Bristol-Myers Squibb Co. and Pfizer Inc with permission of American College of Physicians - Journals, from Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: an Analysis of Real-World Data, Dawwas GK et al. *Ann Intern Med*. 2022. doi:10.7326/M21-0717; permission conveyed through Copyright Clearance Center, Inc.

DVT=deep vein thrombosis; PE=pulmonary embolism; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- **Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS):** Direct-acting oral anticoagulants (DOACs), including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

ADVERSE REACTIONS

- The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding in adult patients.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

STUDY DESIGN AND OBJECTIVE

INDEPENDENTLY FUNDED
REAL-WORLD DATA ANALYSIS

Eliquis[®]
(apixaban) tablets 5mg
2.5mg

Includes patients covered by
commercial healthcare plans³

Adult new users* of XARELTO or ELIQUIS
within 30 days of a VTE hospitalization
(N=49,900)³

XARELTO
(n=21,613)


ELIQUIS
(n=28,287)

1:1 PROPENSITY SCORE MATCHING (PSM)



(n=18,618)

Propensity score matching was
used to reduce differences in baseline
characteristics between both groups.³



(n=18,618)

OBJECTIVE³

The objective of this real-world, retrospective analysis was to compare effectiveness and safety of ELIQUIS to XARELTO for newly prescribed patients with VTE.

PRIMARY EFFECTIVENESS OUTCOME³

Composite: Recurrent deep vein thrombosis (DVT) or pulmonary embolism (PE).

PRIMARY SAFETY OUTCOME³

Composite: Gastrointestinal (GI) bleeding or intracranial bleeding.[†]

COMPONENTS OF COMPOSITE OUTCOMES³

DVT, PE, GI bleeding,[†] intracranial bleeding.[†]

*New user was defined as patients without use of apixaban or rivaroxaban during the 12-month look-back period.³

[†]Did not consider bleeding events documented in the outpatient setting, but rather focused on bleeding resulting in hospitalization.³

VTE=venous thromboembolism.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

SELECT BASELINE CHARACTERISTICS³

INDEPENDENTLY FUNDED
REAL-WORLD DATA ANALYSIS

Eliquis[®]
(apixaban) tablets 5mg
2.5mg

	ELIQUIS (n=18,618)	XARELTO (n=18,618)
AFTER 1:1 PROPENSITY SCORE MATCHING		
AGE, YEARS (MEAN)	67.4	67.5
SEX		
Male	47.5%	47.4%
Female	52.5%	52.5%
VTE TYPE*		
Provoked VTE	42.2%	42.2%
Unprovoked VTE	56.5%	56.5%
BASELINE COMORBIDITIES		
Anemia	15.1%	15.0%
Angina	2.3%	2.3%
Cancer	21.4%	22.4%
Chronic kidney disease	30.5%	31.0%
Coronary artery disease	1.2%	1.2%
Diabetes	29.5%	29.4%

Baseline characteristics were assessed up to 12 months before the cohort entry date.³

This is not a complete list of baseline characteristics. Additional baseline characteristics were assessed with this analysis.³

All baseline characteristics were well balanced after PSM (standardized difference <0.1).³

*Users were classified based on incident VTE type into 2 groups: VTE provoked by transient risk factors (for example, trauma, pregnancy, postpartum, surgery), and VTE that was either provoked by chronic risk factors (for example, cancer) or unprovoked.³

PSM=propensity score matching; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

- ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

SELECT BASELINE CHARACTERISTICS³ (cont'd)

INDEPENDENTLY FUNDED
REAL-WORLD DATA ANALYSIS

Eliquis[®]
(apixaban) tablets 5mg
2.5mg

	ELIQUIS (n=18,618)	XARELTO (n=18,618)
BASELINE COMORBIDITIES (cont'd)		
End-stage renal disease	1.5%	0.4%
Heart failure	19.4%	19.5%
Hemophilia	0.2%	0.2%
Hypertension	68.7%	69.0%
Stroke	19.4%	17.5%
Transient ischemic attack	14.7%	14.5%
Ulcer	6.8%	6.9%
BASELINE MEDICATIONS[†]		
Antiplatelet	12.6%	12.6%
NSAIDs	21.2%	21.1%
Proton-pump inhibitors	29.0%	29.1%

Baseline characteristics were assessed up to 12 months before the cohort entry date.³

This is not a complete list of baseline characteristics. Additional baseline characteristics were assessed with this analysis.³

All baseline characteristics were well balanced after PSM (standardized difference <0.1).³

[†]Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use with oral anticoagulants increases the risk of bleeding.¹

NSAID=nonsteroidal anti-inflammatory drug.

SELECTED IMPORTANT SAFETY INFORMATION

DRUG INTERACTIONS

- **Combined P-gp and Strong CYP3A4 Inhibitors:** Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors.

Clarithromycin

Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.

- **Combined P-gp and Strong CYP3A4 Inducers:** Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban.
- **Anticoagulants and Antiplatelet Agents:** Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

METHODS OF ANALYSIS³

INDEPENDENTLY FUNDED
REAL-WORLD DATA ANALYSIS

Eliquis[®]
(apixaban) tablets 5mg
2.5mg

Study date: 01/01/2015–06/30/2020

Index drug: ELIQUIS or XARELTO

Index date: Date of first prescription of ELIQUIS or XARELTO

Baseline period: 12 months prior to index date

Data source: Optum[®] Clinformatics[®]

DATA SOURCE

- Optum[®] Clinformatics[®] database captured commercial data in the United States. It included deidentified individual-level data on enrollment, patient demographics, outpatient claims, inpatient claims, prescription drug claims, and laboratory data for a subset of patients

INCLUSION CRITERIA

- Patients with VTE were identified by inpatient claims using International Classification of Diseases, Ninth Revision (ICD-9) and International Classification of Diseases, Tenth Revision (ICD-10) codes (415.1, 453.8, 453.2, 451.2, 451.9, 453.1, 453.9, I82.4, I82.9, I26.0, I26.9, 451.19, 451.81, 451.83, 451.89, 451.11) in the primary or principal position between 1/1/2015 and 6/30/2020
- Patients ≥18 years who initiated treatment with ELIQUIS or XARELTO within 30 days of diagnosis
- “New user” was defined as the absence of prior use of any anticoagulants during baseline period

EXCLUSION CRITERIA

- Less than 12 months of continuous enrollment before cohort entry
- History of prior dispensing of any anticoagulant during the baseline period
- History of DVT or PE during the baseline period (before index VTE diagnosis)

NOTE: Patients with mechanical heart valve were not excluded from this study. This was a small subset of patients (0.5%). The use of ELIQUIS or XARELTO is not recommended in patients with prosthetic heart valves.^{1,3,9}

Optum[®] is a registered trademark of Optum, Inc. and Clinformatics[®] is a registered trademark of Optuminsight, Inc.

ATE=average treatment effects; ATT=average treatment effects on the treated; CI=confidence interval; DVT=deep vein thrombosis; GI=gastrointestinal; HR=hazard ratio; IPTW=inverse probability of treatment weighting; PE=pulmonary embolism; PS=propensity score; PSM=propensity score matching; VTE=venous thromboembolism.

OUTCOMES

- Composite effectiveness endpoint of recurrent DVT or PE with hospitalization, based on ICD codes in principal position
- Composite safety endpoint of GI or intracranial bleeding with hospitalization, based on ICD codes in principal position
 - Bleeding other than GI or intracranial were not included
- Components of the composite endpoints were also analyzed separately

STATISTICAL ANALYSIS

- 1:1 PSM was employed to balance baseline characteristics between the ELIQUIS and XARELTO arms
- Cox proportional hazard models were used after PSM to estimate the HRs and 95% CIs for the outcomes. The model was adjusted for the calendar year
- **Sensitivity analyses were consistent with the primary analysis and included:**
 - Used IPTW average treatment effects (ATE) and average treatment effects on the treated (ATT) as methods of adjustment instead of matching. The IPTW method balances the characteristics of the two cohorts, while preserving the full sample size that met the inclusion criteria of the study³
 - Increased the gap between contiguous refills from 7 days to 15 days and 30 days
 - Symmetrically trimmed the tails of PS to remove extreme observations
 - Included VTE events occurring in the outpatient setting in the outcome definition
 - Examined the incidence of prostate cancer and breast cancer as negative control outcomes

FOLLOW-UP PERIOD

- Follow-up period began on cohort entry date and continued until the end of the study period (June 30, 2020), the occurrence of a study outcome of interest, discontinuation of the index medication, start of a comparator, or end of health plan enrollment for more than 30 days
- Median follow-up was 102 days for new ELIQUIS users and 105 days for new XARELTO users

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including Boxed WARNINGS.

LIMITATIONS OF ANALYSIS

STUDY DESIGN/DEFINITION

- Due to the nature of retrospective, observational cohort studies, no causal relations could be inferred, and only statistical associations were assessed¹⁰
- In contrast to clinical trials, outcomes were defined by using ICD-9 and ICD-10 diagnosis codes rather than outcome adjudication^{3,5}
- The presence of a claim for a filled prescription does not indicate whether the medication was consumed or taken as prescribed by the US prescribing information

BIAS/CONFOUNDING^{3,7,11}

- Although cohorts were PS-matched, residual confounding is possible due to unmeasured factors such as lack of information available on body mass index, lifestyle variables, or over-the-counter medications such as aspirin. This limitation is especially important for interpreting direct oral anticoagulant (DOAC) vs DOAC comparison, which are for hypothesis generation, and therefore results should be interpreted with caution

DATA COLLECTION³

- Exposure misclassification is possible because some patients may have overstocked medications and taken longer times to pick up their next prescription from an outpatient pharmacy
- Outcome misclassification is possible because of the diagnostic codes that were used for billing purposes
- Only severe outcomes resulting in hospitalization were included and not those presenting in the outpatient setting
- There was a lack of information on adherence
- Death data was not available
- Laboratory values were not available for all patients

GENERALIZABILITY³

- The cohort was restricted to commercially insured patients with VTE, which limited the generalizability to other populations. Because propensity score matching resulted in the loss of participants, the estimated effect may not generalize to the unmatched population. However, study results were consistent when using other statistical methods of adjustment IPTW

FOLLOW-UP

- Relatively short follow-up: median follow-up was 102 days for new ELIQUIS users and 105 days for new XARELTO users^{1,3}
- The study had a shorter follow-up relative to the clinical trials of DOACs³

ICD-9=International Classification of Diseases, Ninth Revision; ICD-10=International Classification of Diseases, Tenth Revision; IPTW=inverse probability of treatment weighting; PS=propensity score; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

PREGNANCY

- The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery, and in the fetus and neonate.
 - *Labor or delivery:* ELIQUIS use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

INCIDENCE OF RECURRENT VTE AND BLEEDING

INDEPENDENTLY FUNDED
REAL-WORLD DATA ANALYSIS




EFFECTIVENESS*³

COMPOSITE OF RECURRENT DVT/PE
HR=0.77 (95% CI: 0.69–0.87)

SAFETY*³

COMPOSITE OF GI/INTRACRANIAL BLEEDING
HR=0.60 (95% CI: 0.53–0.69)



Retrospective, observational analyses are not intended for direct comparison with clinical trials and are designed to evaluate associations among variables; causality cannot be established in observational analyses.^{5,7,11}

The definitions of recurrent VTE, bleeding, follow-up period, and the patient population in AMPLIFY were different than in this analysis.^{1,3}

Unlike in AMPLIFY, no enoxaparin/warfarin comparator arm was included in this analysis.^{3,8}

Other studies (including RCT and RWD analyses) in adult patients comparing ELIQUIS with other DOACs, which may have used different methods, populations, and outcome definitions, have shown different findings.

†RRR was calculated as $(1 - HR) \times 100$. ARR was calculated as the difference between the incidence rates and is expressed per 100 person-years.³

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.¹

*Outcomes were based on ICD-9 and ICD-10 codes listed in the primary position in the inpatient discharge claims.³

Sensitivity analysis that used IPTW ATE instead of PSM for adjustment yielded similar results (ELIQUIS vs XARELTO): Recurrent VTE: HR=0.80 (95% CI: 0.72–0.89); Bleeding events: HR=0.60 (95% CI: 0.54–0.67).³

ARR=absolute risk reduction; ATE=average treatment effects; CI=confidence interval; DOAC=direct oral anticoagulant; DVT=deep vein thrombosis; GI=gastrointestinal; HR=hazard ratio; ICD-9=International Classification of Diseases, Ninth Revision; ICD-10=International Classification of Diseases, Tenth Revision; IPTW=inverse probability of treatment weighting; PE=pulmonary embolism; PSM=propensity score matching; RRR=relative risk reduction; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

LACTATION


- Breastfeeding is not recommended during treatment with ELIQUIS.

FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

- Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. The risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including Eliquis should be assessed in these patients and those with abnormal uterine bleeding.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

COMPONENTS OF COMPOSITE: INCIDENCE OF RECURRENT DVT AND RECURRENT PE



Retrospective, observational analyses are not intended for direct comparison with clinical trials and are designed to evaluate associations among variables; causality cannot be established in observational analyses.^{5,7,11}

The definitions of recurrent VTE, bleeding, follow-up period, and the patient population in AMPLIFY were different than in this analysis.^{1,3}

Unlike in AMPLIFY, no enoxaparin/warfarin comparator arm was included in this analysis.^{3,8}

Other studies (including RCT and RWD analyses) in adult patients comparing ELIQUIS with other DOACs, which may have used different methods, populations, and outcome definitions, have shown different findings.

*Outcomes are based on first VTE event and based on ICD-9 and ICD-10 codes listed in the primary position in the inpatient discharge claims.³

CI=confidence interval; DOAC=direct oral anticoagulant; DVT=deep vein thrombosis; HR=hazard ratio; ICD-9=International Classification of Diseases, Ninth Revision; ICD-10=International Classification of Diseases, Tenth Revision; PE=pulmonary embolism; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

- **Increased Risk of Thrombotic Events after Premature Discontinuation:** Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.


Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

COMPONENTS OF COMPOSITE: INCIDENCE OF GI AND INTRACRANIAL BLEEDING

SAFETY*³

GASTROINTESTINAL BLEEDING
HR=0.60 (95% CI: 0.53–0.69)

INTRACRANIAL BLEEDING
HR=0.54 (95% CI: 0.14–1.20)



Retrospective, observational analyses are not intended for direct comparison with clinical trials and are designed to evaluate associations among variables; causality cannot be established in observational analyses.^{5,7,11}

The definitions of recurrent VTE, bleeding, follow-up period, and the patient population in AMPLIFY were different than in this analysis.^{1,3}

Unlike in AMPLIFY, no enoxaparin/warfarin comparator arm was included in this analysis.^{3,8}

Other studies (including RCT and RWD analyses) in adult patients comparing ELIQUIS with other DOACs, which may have used different methods, populations, and outcome definitions, have shown different findings.

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.¹

*Outcomes are based on first bleeding event and based on ICD-9 and ICD-10 codes listed in the primary position in the inpatient discharge claims.³

CI=confidence interval; DOAC=direct oral anticoagulant; GI=gastrointestinal; HR=hazard ratio; ICD-9=International Classification of Diseases, Ninth Revision; ICD-10=International Classification of Diseases, Tenth Revision; VTE=venous thromboembolism.

SELECTED IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- **Bleeding Risk:** ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
 - Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
 - Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
 - The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available for adults. Please visit www.andexxa.com for more information on availability of a reversal agent.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.

REFERENCES

1. Eliquis® (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc, New York, NY.
2. Agnelli G, Buller HR, Cohen A, et al for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*. 2013;36(protocol):799-808.
3. Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. *Ann Intern Med*. 2022;175:20-28.
4. Stanley K. Design of randomized controlled trials. *Circulation*. 2007;115:1164-1169.
5. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. *JACC Cardiovasc Interv*. 2008;1:211-217.
6. Kovesdy CP, Kalantar-Zadeh K. Observational studies vs randomized controlled trials: avenues to causal inference in nephrology. *Adv Chronic Kidney Dis*. 2012;19:11-18.
7. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. *Value Health*. 2007;10:326-335.
8. Agnelli G, Buller HR, Cohen A, et al for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*. 2013;369:799-808.
9. Xarelto® (rivaroxaban) Package Insert. Janssen Pharmaceuticals Inc, Titusville, NJ.
10. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. *Chest*. 2016;150:1302-1312.
11. Silverman SL. From randomized controlled trials to observational studies. *Am J Med*. 2009;122:114-120.
12. Jin MC, Sussman ES, Feng AY, et al. Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients. *Thromb Res*. 2021;204(suppl appendix):126-133.
13. Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. *Lancet Haematol*. 2019;6:e20-e28.
14. Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. *Blood Adv*. 2019;3:2381-2387.
15. Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. *J Thromb Thrombolysis*. 2015;39:155-165.
16. Sindet-Pedersen C, Staerk L, Pallisgaard JL, et al. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. *Eur Heart J Cardiovasc Pharmacother*. 2018;4:220-227.
17. Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. *PLoS One*. 2015;10:e0144856.
18. Lutsey PL, Zakai NA, MacLehose RF, et al. Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism. *Br J Haematol*. 2019;185:903-911.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including Boxed WARNINGS.

REFERENCES (cont'd)

19. Bott-Kitslaar DM, McBane RD, Casanegra AI, et al. Apixaban and rivaroxaban in patients with acute venous thromboembolism. *Mayo Clin Proc.* 2019;94:1242-1252.
20. Howe Z, Naville-Cook C, Cole D. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. *J Thromb Thrombolysis.* 2019;47:280-286.

Please see additional Important Safety Information throughout and [click here](#) for U.S. Full Prescribing Information, including **Boxed WARNINGS**.



ELIQUIS[®] and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company.
All other trademarks are property of their respective companies.
© 2025 Bristol-Myers Squibb Company. All rights reserved. 432-US-2500329 08/25